Medtronic Inc (MDT) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Medtronic Inc (MDT)

90.65

-0.58 (0.64%)

as of Aug 31, 2026, 8:00:00 pm Market Open.

183 watching

Investor Insights

Aug 31, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

Medtronic Inc (MDT) is viewed positively by various experts, benefiting from demographic tailwinds as the aging Baby Boomer population becomes a relevant customer base. The company is currently trading at a price-to-earnings (PE) ratio of 15x, complemented by a solid 7% free cash flow yield and anticipated earnings growth of 8-9% over the next several years. Recent momentum has seen the stock rise 20% in the past three months, suggesting strong market interest as it approaches its upcoming earnings report. Despite competition, particularly from Boston Scientific, Medtronic's diversified portfolio sets it apart from peers who may lack similar R&D capabilities. While short- to medium-term outlook is optimistic, some experts caution against viewing Medtronic as a long-term investment due to potential challenges in maintaining leadership and innovation in the industry.

Consensus

Positive

Valuation

Undervalued

Similar

Stryker,SYK

BUY

Aging demographics help. It's selling below 2x below its 5-year average, and has a 6% operating cash flow yield. He expects solid earnings next week.

Wealthica Track your Stocks in your Watch List

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly This $124 billion market cap manufacturer of medical devices ranging from insulin pumps to pacemakers is the world's largest in its class. It has raised dividends for 46 consecutive years. It has been buying back stock while maintaining steady cash reserves and trades at just 2.4x earnings. The resumption in surgical procedures as the pandemic calms down is expected to lead to substantial uplift in EPS going forward. We recommend setting a stop loss at $79, looking to achieve $117 -- upside over 25%. Yield 2.92% (Analysts’ price target is $117.13)

PAST TOP PICK

(A Top Pick Jan 15/21, Down 7%) Company has increased dividend for almost 50 years, however needs a good acquisition to grow. Stock price is low which creates a buying opportunity. Will continue to buy and hold.

HOLD

Relatively low growth at 3-5%, value stock with a 13.5-14.5x multiple. Couple of missteps. Competitive threats. One of the largest medical device companies. Tends to attract money flows when markets get volatile. Reports later in February. Mild inflationary pressures. OK dividend. OK to hold over time, but if you want more growth, pair it with something like BSX.

SELL

They've been executing badly. Sell this and buy EW-N

WAIT

MDT vs. BSX Two great companies. In the implantable medical device business. Loves the area. Too expensive, as investors have flocked to them and the multiple has increased. Would love to own both if prices came down substantially.

BUY

Healthcare is an interesting area, especially with a slant toward medical devices. This is a safe and steady name, significant track record of dividend increases.

BUY

They report Thursday. Boring, but he predicts stellar numbers. Their medical devices are being installed in record numbers post-pandemic. There's a lot of pent-up demand from all these delayed surgeries.

BUY ON WEAKNESS

Allan Tong’s Discover Picks Up 14.68% since August 18, 2020 MDT was trading at $101. It has since climbed as high as $122.15, but now lockdowns are delaying elective surgeries, and the stock is starting to wobble around $117. Keep an eye on this, because continuing lockdowns and a general market pullback would make this a buy again. Right now, MDT is pricey, trading at a 43x PE, which is nearly double from last April and the highest level in 12 months. Its divvy pays nearly 2%. Analysts target the stock at $129.26, based on 17 buys and three holds. Read 2 Successful Past Picks: Nuvei & Medtronic for our full analysis.

TOP PICK

The global leader in med-tech space by revenue. It has increased dividends for 42 consecutive years. 9.4% total return for the last 5 years. Benefits from the aging demographics. Does a lot of tuck in acquisitions. The top line is growing at 9% in the last 10 years. (Analysts’ price target is $128.84)

BUY

Likes this medical device-maker. They presented at today's JPMorgan's healthcare conference. The stocked slipped 1% today after the company trimmed organic growth forecast this quarter because the explosion of Covid cases is forcing the postponement of medical procedures. This happened at a previous conference, so he's not surprised. The Covid issue is temporary and meanwhile more people will get vaccinated that will unleash pent-up demand for MDT's devices.

BUY

There is a backlog of elective surgeries. This is a good area of the industry to be in. She chose JNJ-N but MDT-N is a good candidate too.

BUY

A large medical tech company, one of the largest in that field. It is a nice industry that he likes. They deliver consistent earnings growth. It is more of an oligopoly market. It could be a core holding in a portfolio to get medical technology exposure. He holds BSX-N, however.

BUY ON WEAKNESS

Sales could be light, because people may be light, because it makes medical devices and people are postponing operations due to Covid. If MDT gets hit, buy it, because a Covid vaccine is coming. It reports Tuesday.

BUY

A premier medical device-maker. Their most recent report beat the street. These medical stocks sold off during the lockdown over fears that surgeries would halt indefinitely, but those fears and sell-offs were overdone.

Showing 31 to 45 of 127 entries

Most Recent Experts

Andrey Omelchak

LionGuard Capital Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Medtronic Inc (MDT)